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==============================================

Attention Deficit and Hyperactivity Disorder (ADHD) is a complex childhood disorder characterized by persistent symptoms of inattentiveness, hyperactivity and/or impulsivity. Its prevalence is around 5% worldwide, and varied in different population.^[@R1]--[@R3]^ The Diagnostic and Statistical Manual IV (DSM-IV) classify the disorder in three subtypes: hyperactive, inattentive and combined.

ADHD is a multifactorial disorder^[@R3]^ with heritability estimates around 76% suggesting an important role for genetic factors. Candidate variants, studied mainly in populations of European background, including genes involved in dopaminergic and serotoninergic pathways; and in neural signaling mechanisms.^[@R5]^

Dopaminergic genes comprise *DRD4*, encoding for the dopamine D4 receptor, which is highly expressed in fronto-subcortical system implicated in ADHD pathophysiology.^[@R6]^ A variable number tandem repeat (VNTR) located in exon 3 of *DRD4* gene has been explored in ADHD,^[@R7]^ with the seven-repeat allele being associated with this disorder.^[@R8],[@R9]^ Dopamine D5 receptor (DRD5) is also implicated in ADHD susceptibility. The dinucleotide (CA)n repeat polymorphisms; located near18.5 kb at 5' end to the transcription start site of *DRD5* has been found to be associated in several populations.^[@R10],[@R11]^ The dopamine transporter gene (*SLC6A3*) has been implicated in ADHD pathogenesis due to the fact that some drugs used in its treatment block the dopamine transporter as their mechanism of action.^[@R12]^ Studies with knock-out mice have supported this hypothesis.^[@R13]^ The 10-repeats allele of the 148 bpVNTR located at the 3' untranslated region (UTR) has been found to be more frequent in cases than controls.^[@R11],[@R14],[@R15]^ The dopamine beta hydroxylase gene (*DBH*) is responsible for the conversion of dopamine into noradrenaline. The A2 allele of the Taq1 polymorphism located in intron 5 of this gene has also been implicated in ADHD.^[@R11],[@R16]--[@R18]^

Among serotoninergic genes, the serotonin receptor (*HTR1B*) and the serotonin transporter(*SLC6A4*) have been widely studied in ADHD. The associated polymorphisms include the single nucleotide polymorphism (SNP) c.861G\>C (rs6296)of *HTR1B.*^[@R19],[@R20]^ and the 44-bp insertion/deletion located in the promoter region of *SLC6A4.SLC6A.*^[@R21]--[@R23]^

Despite large evidence of these associations, controversy about results is still remaining. Studies performed in several populations with the different sample sizes methods and demonstrated contradictory results. Meta-analysis studies have also failed contributed to clarify the role of these variants.^[@R24]^ The study of these variants in different populations is therefore needed^[@R5]^ to address the genetic association with disease pathology.

The purpose of this study was to explore the possible association of six polymorphic variants located in candidate genes in a sample of Colombian ADHD patients.

Methods {#s2}
=======

Subjects {#s2a}
--------

Children between 6 and 15 years old from the city of Bogotá, Colombia were included. DSM-IV criteria and Behavior Assessment System for Children (BASC) were applied to parents and teachers of patient, in order to confirm the diagnosis. The Wechsler scale of intelligence (WISC-R) was applied in order to exclude children with a score less than 70, which indicate an intellectual disability. Cases were selected among children who had at least one of the following criteria (applied to information derived from parents or teachers): 1) Six or more points, over nine, for inattention in the DSM-IV criteria and a percentile over 85 in the inattention domain of BASC; 2) Six or more points, over nine, for hyperactivity in the DSM-IV criteria and a percentile over 85 in the hyperactivity domain of BASC. The patient's group included 86 children.

Children who did not meet ADHD criteria, did not have intellectual disability (WISC-R \>70) or other neurological disorders, were included in the study as controls (n = 56). In order to have a bigger sample size, an additional 96 DNA samples were included, among children or adults who did not have a history of ADHD or any other cognitive, neurological or psychiatric disorder. Finally, the control group included 152 subjects.

Peripheral blood or buccal samples were taken from all subjects and parents of cases. Parents of cases and controls approved and signed the informed consent after a detailed explanation. The Institutional Ethical Committee approved this study (Act 117, May 29^th^,2008). To increase DNA samples, an amendment was presented to the ethical committee and approved by the act 165 of May 13^th^ 2010.

DNA extraction {#s2b}
--------------

DNA extraction was carried out from peripheral blood or buccal samples using conventional techniques.

Genotyping {#s2c}
----------

VNTRs in *DRD4* and *SLC6A3* as well as the insertion/deletion in the promoter region of *SLC6A4* genes were genotyped by PCR followed by electrophoretic analysis as previously described.^[@R25],[@R26]^ DNA amplification reactions were performed with GoTaq^®^ Green Master Mix (Promega), using the following cycling conditions: 94°C for 10 min, followed by 30 cycles of 94°C for 45 sec, 61°C for 45 sec, 72°C for 45 sec. Amplification was completed with a final elongation step of 72°C for 10 min. Fragments were separated on 1,2% agarose gels and visualized using ethidium bromide.

Polymorphisms in *DBH* (Taq1 A polymorphism) and *HTR1B* (rs6296) genes were genotyped by PCR-RFLP. For *HTR1B* the PCR product was digested with HincII restriction enzyme at 37°C overnight, and the PCR product of *DBH* was digested with Taq1 at 61°C for 16 hours. The alleles were detected after separation on an agarose gel. Experimental approaches were used as published before.^[@R27],[@R28]^

The dinucleotide (CA)n repeat polymorphism located in the *DRD5* gene was genotyped using PCR with fluorescently labeled primers, followed by capillary electrophoresis in an ABI 3500 sequencer.^[@R29]^ Genotypes were analysed with Gene Mapper 4.1 software (Applied Biosystems).

Statistical Analysis {#s2d}
--------------------

Statistical analysis was carried out by two different approaches. First, a transmission disequilibrium test (TDT) was done in 86 trios: corresponding to the index cases and their two biological parents. This analysis was used to test if there was preferential allelic transmission for any of the six polymorphisms. Genotype data was analyzed using PLINK.^[@R30]^ PLINK is a commonly used program for analysis of genetic studies, which is freely available and uses two main files as input: PED and MAP files.

A second complementary analysis was done through a case-control study where 73 cases and 152 controls were included. An analysis was performed for polymorphic variants in *HTR1B* and *SLC6A4* genes (because these were found to be associated more frequently with the disorder^[@R24]^), using PLINK and SNPStat software.^[@R30],[@R31]^Results for TDT and case control analysis were based in a X^2^ statistic and corrected for multiple testing with a Bonferroni correction.

Results {#s3}
=======

Cases were classified in subtypes according to DSM-IV criteria and BASC. Combined cases corresponded to 50.7%, 35.6% cases catergorized as inattentive and 13.7% were hyperactive.

Genotype and allele frequencies are presented in [Table 1](#tbl_1){ref-type="table"}. For VNTR in *DRD4*, alleles of two, four, seven and eight repeats were found. For the dinucleotide of *DRD5* more than ten alleles of several molecular weights were found, but a predominant allele of 148 bp was evident. Therefore alleles were grouped into the allele with a molecular weight of 148 bp and others, named "No 148 bp". Only two alleles were found for the VNTR of *SLC6A3*, corresponding to alleles of nine and ten repeats. In *DBH* gene, the Taq1 A polymorphism gives only two alleles (A1 and A2) distinguished by the presence or not of this restriction site, respectively. The alleles of the studied SNP in *HTR1B* corresponded to the presence of a cytosine or a guanine in the position 861 of the gene coding region. Finally, the alleles corresponding to the 44-bp insertion/deletion of *SLC6A4* are called L and S (for large and short respectively) distinguished by a difference of plus (insertion) 44-bp or minus (deletion) 44-bp respectively. We found a larger than expected deletion (approximately 100 bp) in the promoter region of *SLC6A4* gene in only one patient, which we determined as an atypical shorter allele, but no further analysis was implemented in this sample.All polymorphisms studied here were in Hardy Weinberg equilibrium (p\>0.05). [Figure 1](#fig_1){ref-type="fig"} shows the electrophoretic gels for the polymorphisms studied through a PCR-based technique.

###### Allele and Genotype Frequencies

             Allele frequency                                    Genotype Frequency                                          
  ---------- --------------------------------------------------- ------------------------------- ------- ------------------- -------
  *DRD4*     VNTR                                                2                               0,08    2/2                 0,005
             (exon 3)                                            4                               0,69    2/4                 0,112
                                                                 8                               0,21    2/7                 0,015
                                                                                                 0,02    2/8                 0
                                                                                                         4/4                 0,477
                                                                                                         4/7                 0,29
                                                                                                         4/8                 0,005
                                                                                                         7/7                 0,091
                                                                                                         7/8                 0,005
  *DRD5*     Dinucleotide (CA)n (18,5 kb 5' to the start site)   148 bp                          0,395   148bp/148bp         0,140
                                                                 No 148 bp                       0,605   148bp/No 148bp      0,368
                                                                                                         No 148bp/No 148bp   0,491
  *SLC6A3*   40 bp VNTR (3'UTR)                                  9                               0,208   9/9                 0,071
                                                                 10                              0,792   9/10                0,276
                                                                                                         10/10               0,654
  *DBH*      TaqI A (intron 5)                                   A1                              0,302   A1/A1               0,052
                                                                 A2                              0,698   A1/A2               0,5
                                                                                                         A2/A2               0,448
  *HTR1B*    rs6296(coding region)                               C                               0,439   C/C                 0,201
                                                                 G                               0,561   C/G                 0,476
                                                                                                         G/G                 0,323
  *SLC6A4*   44 bp insertion/ deletion (promoter)                L                               0,509   S/S                 0,25
                                                                 S                               0,488   S/L                 0,476
                                                                 Atypical shorter allele (ASA)   0,003   ASA/L               0,006
                                                                                                         L/L                 0,268

![(A) Genotyping of VNTR located in exon 3 of *DRD4*. Lines 1 and2: Heterozygote 2/4, Lines 3, 5, 6: Heterozygote 4/7, Line 4: Homozygote 4/4, Line 7: 50 bp ladder. (B) Genotyping of VNTR located in the 3'UTR of SLC6A3. Line 1: Homozygote 9/9, Line 2: Heterozygote, Line 3: Homozygote 10/10, Line 4: 50 bp ladder. (C) Genotyping of TaqIA polymorphism in DBH. Lines 1 and 2: Heterozygote, Line 3: 50 bp ladder, Line 4: homozygote A1/A1, Line 5: homozygote A2/A2. (D) Genotyping of SNP rs6296 of HTR1B. Line 1: Homozygote C/C, Lines 2 and 3: Homozygote G/G, Line 4: 100 bp ladder, Line 5: Negative control, Line 6: Heterozygote. (E) Genotyping of the 44-bp insertion/deletion in SLC6A4. Lines 1 and 5: Heterozygote, Lines 2 and 3: Homozygote S/S, Line 6: Homozygote L/L.](ANS0972-7531-22-217-g002){#fig_1}

As TDT study only allows two alleles to be analyzed, the two most frequent alleles were considered for polymorphisms having more than two alleles. For example, for the VNTR of *DRD4,* the 4 and 7-repeats allele were considered as they were the most prevalent. Similarly, for *SLC6A4* where three alleles were found, only L and S alleles were included in analysis based on their higher prevalence.

Association analysis through TDT did not demonstrate a preferential allelic transmission for any of the studied polymorphisms when ADHD or its subtypes were evaluated. This is probably due to a high homozygosity percentage for some variants, leading to exclusion of several trios and therefore leads to reduced sample size in TDT analysis ([Table 2](#tbl_2){ref-type="table"}).

###### TDT association analysis

  Gene       A1       A2    T    U    OR      CHISQ   p        Exclusion %
  ---------- -------- ----- ---- ---- ------- ------- -------- -------------
  *SLC6A3*   9        10    17   24   0,708   1,195   0,2743   49,30%
  *DBH*      A1       A2    38   46   0,826   0,762   0,3827   30,10%
  *DRD4*     7        4     21   25   0,832   0,923   0,4531   28,13%
  *DRD5*     No-148   148   32   33   0,922   0,015   0,9513   42,16%
  *HTR1B*    C        G     38   39   0,974   0,013   0,9093   16,20%
  *SLC6A4*   S        L     33   43   0,767   1,316   0,2513   22,90%

Case-control analysis for variants in *HTR1B* and *SLC6A4* genes did not show evidence of association with ADHD susceptibility ([Table 3](#tbl_3){ref-type="table"}).

###### Allelic and Genotype Association using case-control approach

  Gene       MAF      Allelic Association (p\*)   Genotype Association (p\*)
  ---------- -------- --------------------------- ----------------------------
  *HTR1B*    0,4231   0,2371                      0,2919
  *SLC6A4*   0,4686   0,689                       0,7071

Discussion {#s4}
==========

Although several works suggest an important influence of inherited factors in the development of ADHD, these genetic studies involving candidate polymorphisms reveal that the genetic architecture of this disorder is extremely complex.^[@R5],[@R32]^

Several epidemiological and statistical approaches, in populations of different genetic background, has led to controversial results.^[@R5]^

Despite the fact that several candidate genes have a biological role in to ADHD pathophysiology, some studies have failed to find a significant association.^[@R17],[@R33],[@R34]^ Our TDT study performed in the population of Colombian ADHD patients also failed to find a significant relationship with several candidate genes. Since we did not have previous data for homozygosity for these variants in Colombia population, we could not determine a percentage of trio exclusion before the study, which was as high as 49.3% for some genes (*SLC6A3* for example). The high percentage of excluded trios led to small sample size for several variants. A complementary case control approach also failed to find a significant association in our samples.

As ADHD is a complex disease, it is possible that each single polymorphism has a relatively small contribution to the overall risk, but all variants together could underlie a large genetic influence.^[@R35]^ This hypothesis presupposes large sample size in order to find the relation of a specific variant with this disorder. Therefore a large sample of well-characterized patients is a challenge for research groups in developing countries.

Additionally, it is well known that ADHD is highly heterogeneous and has a clinical overlap with other neuropsychiatric conditions,^[@R36]^ making it difficult to associate a single variant with a single phenotype.^[@R35]^ The clinical heterogeneity of ADHD and other neuropsychiatric disorders has opened the door for the study of endophenotypes as a good approach in genetic studies. Endophenotypes refer to the analysis of specific behavioral symptoms, among others, as more stable and less heterogeneousphenotypes.^[@R37]^ Other studies from our group, for example, have shown the contribution of a polymorphism located in *SLC6A3 (DAT1)* gene to the development of an ADHD endophenotype in a Colombian sample.^[@R38]^ We have also previously found an association between two polymorphisms of *SNPA25* and ADHD.^[@R39]^

Conclusions {#s5}
===========

Our study has failed to demonstrate an association of six polymorphic variants located in different candidate genes and the susceptibility to ADHD in Colombian population. Our findings are in concordance with results from genetic studies other populations.^[@R24],[@R40]^ Future prospects in the genetic study of ADHD might include analysis of related endophenotypes.
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